Form 13-F position report

BENITEC BIOPHARMA INC COM NEW

Reported by STATE STREET CORPORATION

BNTC CUSIP 08205P100 Manager CIK 0000093751

Reported 0 shares, down 21,438 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2023
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 10 Through Q3 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 55000
2022-03-31 50000
2022-06-30 25000
2022-09-30 8000
2022-12-31 3644
2023-03-31 4500
2023-06-30 5113
2023-09-30 0
2024-12-31 203217
2025-03-31 275682
2025-06-30 1884554
2025-09-30 3064124
2025-12-31 3300837
2026-03-31 3602352
2026-06-30 5057279
2026-09-30 4275150

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for BENITEC BIOPHARMA INC COM NEW held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 427,515 +49,542 (13.1%) < 0.01% $4,275,150 2026-11-12
Q2 2026 Added 377,973 +39,724 (11.7%) < 0.01% $5,057,279 2026-08-07
Q1 2026 Added 338,249 +93,198 (38.0%) < 0.01% $3,602,352 2026-05-15
Q4 2025 Added 245,051 +26,653 (12.2%) < 0.01% $3,300,837 2026-02-13
Q3 2025 Added 218,398 +57,325 (35.6%) < 0.01% $3,064,124 2025-11-14
Q2 2025 Added 161,073 +139,883 (660.1%) < 0.01% $1,884,554 2025-08-14
Q1 2025 Added 21,190 +5,100 (31.7%) < 0.01% $275,682 2025-05-15
Q4 2024 New 16,090 +16,090 (0.0%) < 0.01% $203,217 2025-02-14
Q3 2023 Reduced 0 -21,438 (-100.0%) 0 $0 2023-11-14
Q2 2023 Unchanged 21,438 0 (0.0%) < 0.01% $5,113 2023-08-14
Q1 2023 Unchanged 21,438 0 (0.0%) < 0.01% $4,500 2023-05-15
Q4 2022 Unchanged 21,438 0 (0.0%) < 0.01% $3,644 2023-02-14
Q3 2022 Unchanged 21,438 0 (0.0%) < 0.01% $8,000 2022-11-15
Q2 2022 Unchanged 21,438 0 (0.0%) < 0.01% $25,000 2022-08-15
Q1 2022 Added 21,438 +438 (2.1%) < 0.01% $50,000 2022-05-16
Q4 2021 Unchanged 21,000 0 (0.0%) < 0.01% $55,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

18 managers reported BENITEC BIOPHARMA INC COM NEW for Q3 2023.

Managers reporting BENITEC BIOPHARMA INC COM NEW in Q3 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Rosenberg Matthew Hamilton Unchanged 23 0 < 0.01% $70 4 qtrs
MORGAN STANLEY Reduced 0 -38,600 0 $0 7 qtrs
GROUP ONE TRADING L P Reduced 0 -1,500 0 $0 9 qtrs
VANGUARD GROUP INC Reduced 0 -74,773 0 $0 11 qtrs
Virtu Financial LLC Reduced 0 -52,869 0 $0 12 qtrs
Tower Research Capital LLC TRC Reduced 0 -7,465 0 $0 7 qtrs
Cutler Group LLC CA Reduced 0 -1,000 0 $0 5 qtrs
WealthTrust Axiom LLC Reduced 0 -12,950 0 $0 11 qtrs
CONCOURSE FINANCIAL GROUP SECURITIES INC Unchanged 0 0 0 $0 14 qtrs
UBS Group AG Reduced 0 -347 0 $0 14 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2023
Filed
November 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.